On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33527123.
- Also identified by DOI 10.1093/cid/ciaa726 and PMC identifier 7314253.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In less than 6 months, since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development, with 9 already recruiting into clinical trials posted on ClinicalTrials.gov. The long-term strategy to handle coronavirus disease 2019 (COVID-19) will almost certainly rely on vaccines. But what type of protection can we realistically expect to achieve from vaccines and when?
Medical subject headings
- COVID-19
- Vaccines
- Viral Vaccines